Purespring Positive About Prospects Despite Burst Biotech Bubble

UK Gene Therapy Moving Quickly Towards Clinic

07 Mar 2022

Some investors are shying away from early-stage gene therapy companies, but Richard Francis, CEO of kidney disease specialist Purespring, told Scrip that the pharmaceutical industry's appetite for the field has not waned and the best-equipped companies will flourish.

While the gene therapy field has suffered a series of setbacks of late, with a number of trials being paused due to safety concerns and investors being spooked, the fundamentals of the sector remain in good shape.

That is the view of Richard Francis, ex-head of Sandoz who took over as CEO of the UK's Purespring Therapeutics...